{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:49:30Z","timestamp":1790401770912,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010011","name":"Jiangsu Postdoctoral Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118955","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T14:42:52Z","timestamp":1779028972000},"page":"118955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of NTQ2494, a potent and orally bioavailable inhibitor of AXL kinase for the treatment of human tumors"],"prefix":"10.1016","volume":"315","author":[{"given":"Lin-Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ye","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Zhi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Dan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-You","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-0113","authenticated-orcid":false,"given":"Dan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118955_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-023-00846-8","article-title":"Therapeutic targeting of the functionally elusive TAM receptor family","volume":"23","author":"Miao","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118955_bib2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/373623a0","article-title":"Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6","volume":"373","author":"Varnum","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118955_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102639","article-title":"AXL - a new player in resistance to HER2 blockade","volume":"121","author":"Adam-Artigues","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2026.118955_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","article-title":"AXL in cancer: a modulator of drug resistance and therapeutic target","volume":"42","author":"Tang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118955_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114253","article-title":"Structure-based discovery of receptor tyrosine kinase AXL degraders with excellent anti-tumor activity by selectively degrading AXL and inducing methuosis","volume":"234","author":"Shi","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118955_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116475","article-title":"Recent discovery and development of AXL inhibitors as antitumor agents","volume":"272","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118955_bib7","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri Toni","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118955_bib8","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","article-title":"A selective small molecule inhibitor of axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer","volume":"70","author":"Holland","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118955_bib9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1021\/ml200198x","article-title":"Design, synthesis, and biological evaluation of a series of novel AXL kinase inhibitors","volume":"2","author":"Mollard","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118955_bib10","doi-asserted-by":"crossref","first-page":"10663","DOI":"10.1021\/acs.jmedchem.5c00239","article-title":"Discovery of AB801, a potent and selective inhibitor of AXL receptor tyrosine kinase for use in cancer therapy","volume":"68","author":"Miles","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118955_bib11","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1021\/acs.jmedchem.6b00608","article-title":"4-Oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new axl kinase inhibitors","volume":"59","author":"Tan","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118955_bib12","doi-asserted-by":"crossref","first-page":"10677","DOI":"10.1021\/acs.jmedchem.5c00238","article-title":"Discovery and characterization of potent, selective, and orally bioavailable 7-Azaindazole AXL receptor tyrosine kinase inhibitors","volume":"68","author":"Foley","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118955_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cellimm.2018.05.004","article-title":"A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers","volume":"331","author":"Wei","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ejmech.2026.118955_bib14","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1200\/jco.2015.33.15_suppl.3066","article-title":"Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers","volume":"33","author":"Breij","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118955_bib15","article-title":"AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model","volume":"9","author":"Chen","year":"2021","journal-title":"Phys. Rep."},{"key":"10.1016\/j.ejmech.2026.118955_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102639","article-title":"AXL - a new player in resistance to HER2 blockade","volume":"121","author":"Adam-Artigues","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2026.118955_bib17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.beem.2008.09.012","article-title":"Receptor tyrosine kinase inhibitors in thyroid cancer","volume":"22","author":"Castellone","year":"2008","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2026.118955_bib18","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-10-2527","article-title":"D.M. McDonald, VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer","volume":"71","author":"You","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118955_bib19","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri Toni","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118955_bib20","doi-asserted-by":"crossref","unstructured":"B. Bhatnagar, D. R. Buelow, K. M. Dvorak-Kornaus, S. J. Orwick, J. Y. Jeon, Z. Talebi, A. S. Ruppert, J. S. Blachly, U. Borate, S. D. Baker, DOI: 10.3389\/frhem.2025.1554764.","DOI":"10.3389\/frhem.2025.1554764"},{"key":"10.1016\/j.ejmech.2026.118955_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114316","article-title":"Discovery a series of quinazolin derivatives as potent AXL inhibitors","volume":"237","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118955_bib22","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of Anaplastic lymphoma kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T01:25:31Z","timestamp":1780190731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"alternative-id":["S0223523426004009"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118955","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of NTQ2494, a potent and orally bioavailable inhibitor of AXL kinase for the treatment of human tumors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118955"}}